To improve the understanding of chemo-refractory high-grade serous ovarian cancers (HGSOCs), scientists characterized the proteogenomic landscape of 242 (refractory and sensitive) HGSOCs, representing one discovery and two validation cohorts across two biospecimen types (formalin-fixed paraffin-embedded and frozen). They identified a 64-protein signature that predicts with high specificity a subset of HGSOCs refractory to initial platinum-based therapy and is validated in two independent patient cohorts. They detected significant association between lack of Ch17 loss of heterozygosity (LOH) and chemo-refractoriness.
